CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.
This page is available in